Crystalys Therapeutics
Crystalys Launches With $205M to Advance Dotinurad Globally, Already Approved in China by Eisai
Novo-backed Crystalys Therapeutics raised $205M to advance dotinurad into global Phase 3 trials. Already approved in China and Asia, the once-daily URAT1 inhibitor will target U.S. and European patients with unmet need for second-line gout therapy.